Yahoo Finance

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

CARLSBAD, Calif., January 07, 2026--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, ...
Business Insider

EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome

Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 outperforming placebo throughout the study (final assessment ...
Pharmabiz

GSK reports positive results from B-Well 1 & B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B

GSK plc announced positive results from its two pivotal phase III trials, B-Well 1 [NCT05630807] and B-Well 2 [NCT 05630820], evaluating bepirovirsen, an investigational antisense oligonucleotide (ASO ...
Hosted on MSN

Sino Biopharm advances first-in-class ROCK2 inhibitor TDI01 into global first phase III IPF trial

Sino Biopharmaceutical ( (HK:1177)) just unveiled an update. Sino Biopharmaceutical has announced completion of enrollment of the first patient in a Phase III clinical trial for TDI01, its ...
ascopubs.org

Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors.

A phase I study to evaluate the safety and effectiveness of neoantigen-based personalized dendritic cell vaccine in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2021 ...